Chugai Pharmaceutical Co., Ltd. and Roche Holding AG have announced additional results from the global Phase III COMMODORE 1 and 2 clinical trial program with crovalimab for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), on the basis of which the anti-C5 recycling monoclonal antibody has just been submitted for approval in Japan for this indication.
The data were also presented at the recent European Hematology Association (EHA) Hybrid Congress and will support crovalimab’s further global approval
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?